



## Spyre Therapeutics to Participate in Upcoming November Investor Conferences

October 29, 2025

WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

**Event: Guggenheim 2<sup>nd</sup> Annual Healthcare Innovation Conference - Boston**

**Date:** Monday, November 10, 2025

**Fireside Time:** 10:00 am ET

**Event: Stifel 2025 Healthcare Conference – New York**

**Date:** Tuesday, November 11, 2025

**Fireside Time:** 8:40 am ET

**Event: Jefferies Global Healthcare Conference - London**

**Date:** Wednesday, November 19, 2025

**Fireside Time:** 8:00 am GMT

Live audio webcasts and replays of these events will be available on the Spyre investor events website at <https://ir.spyre.com/events-and-presentations>.

### About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting  $\alpha 4\beta 7$ , TL1A, and IL-23.

For more information, visit Spyre's website at [www.spyre.com](http://www.spyre.com).

**For Investors:**

Eric McIntyre, Spyre Therapeutics

VP of Finance and Investor Relations

[Eric.mcintyre@spyre.com](mailto:Eric.mcintyre@spyre.com)